Replies to post #243 on Arbutus Biopharma Corporation (ABUS)

[Ubertino]

MC3 IP - Alnylam

Results of searching in PCT for:
( PA/Alnylam ) AND ( DE/MC3, AND DE/lipid, AND DE/delivery ): 15 records
Showing records 1 to 15 of 15 :

1. (WO 2011/038031) DUAL TARGETING SIRNA AGENTS 31.03.2011 PCT/US2010/049868 FITZGERALD, Kevin ALNYLAM PHARMACEUTICALS, INC.
2. (WO 2011/034798) LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES 24.03.2011 PCT/US2010/048512 BUMCROT, David ALNYLAM PHARMACEUTICALS, INC.
3. (WO 2011/028938) METHODS FOR LOWERING SERUM CHOLESTROL IN A SUBJECT USING INHIBITION OF PCSK9 10.03.2011 PCT/US2010/047726 RHODES, Jason ALNYLAM PHARMACEUTICALS, INC.
4. (WO 2011/020023) LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF A GENE FROM THE EBOLA VIRUS 17.02.2011 PCT/US2010/045478 DE FOUGEROLLES, Antonin ALNYLAM PHARMACEUTICALS, INC.
5. (WO 2011/017548) LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF EG5 AND VEGF GENES 10.02.2011 PCT/US2010/044594 BUMCROT, David ALNYLAM PHARMACEUTICALS, INC.
6. (WO 2011/005793) CELL-BASED BIOPROCESSING 13.01.2011 PCT/US2010/041106 ROSSOMANDO, Anthony ALNYLAM PHARMACEUTICALS, INC.
7. (WO 2011/005786) COMPOSITIONS AND METHODS FOR ENHANCING PRODUCTION OF A BIOLOGICAL PRODUCT 13.01.2011 PCT/US2010/041099 ROSSOMANDO, Anthony ALNYLAM PHARMACEUTICALS, INC.
8. (WO 2011/005765) BIOPROCESSING 13.01.2011 PCT/US2010/041072 ROSSOMANDO, Anthony ALNYLAM PHARMACEUTICALS, INC.
9. (WO 2010/148013) LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE 23.12.2010 PCT/US2010/038707 FITZGERALD, Kevin ALNYLAM PHARMACEUTICALS, INC.
10. (WO 2010/147992) METHODS FOR INCREASING EFFICACY OF LIPID FORMULATED SIRNA 23.12.2010 PCT/US2010/038679 FITZGERALD, Kevin ALNYLAM PHARMACEUTICALS, INC.
11. (WO 2010/144740) IMPROVED LIPID FORMULATION 16.12.2010 PCT/US2010/038224 CHEN, Jianxin ALNYLAM PHARMACEUTICALS, INC.
12. (WO 2010/129687) METHODS OF DELIVERING OLIGONUCLEOTIDES TO IMMUNE CELLS 11.11.2010 PCT/US2010/033747 NOVOBRANTSEVA, Tatiana ALNYLAM PHARMACEUTICALS, INC
13. (WO 2010/105209) LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES 16.09.2010 PCT/US2010/027210 BUMCROT, David ALNYLAM PHARMACEUTICALS, INC.
14. (WO 2010/068816) GNAQ TARGETED DSRNA COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION 17.06.2010 PCT/US2009/067581 GOLLOB, Jared ALNYLAM PHARMACEUTICALS, INC.
15. (WO 2010/048228) COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN 29.04.2010 PCT/US2009/061381 SAH, Dinah, Wen-yee ALNYLAM PHARMACEUTICALS, INC.

http://www.wipo.int/pctdb/en/search-adv.jsp
Insert - including all brackets!:
(PA/Alnylam) AND (DE/MC3, AND DE/lipid, AND DE/delivery)
in 'search' box and hit "SEARCH".

Looks rather important! No mention of Tekmira. Seems odd that should MC3 have come from Tekmira with a no disclosure agreement that these VERY public patent filings come to light. Does Alnylam not honour their agreements!?

$5 Billion is at stake!

MUST be important and these patent filings indicate to me that Alnylam wants an EXCLUSIVE ownership all to themselves.

In (WO/2010/144740) IMPROVED LIPID FORMULATION - "MC3" is mentioned 60 times.